Study for the effect on blood glucose fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor or to DPP-4 inhibitor/SGLT2 inhibitor combination tablet in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study -

Study for the effect on blood glucose fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor or to DPP-4 inhibitor/SGLT2 inhibitor combination tablet in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study - - The effect on blood glucose fluctuation between DPP-4 inhibitor, SGLT2 inhibitor, and DPP-4 inhibitor/SGLT2 inhibitor combination in patients with type 2 diabetes.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029628

Enrollment

Registered

2017-10-19

Start date

2017-11-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Switching from teneligliptin to canaglifozin Switching from teneligliptin to teneligliptin/canagliflozin combination tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 20 to 80 years old 2) HbA1c 6.5-9.0% (NGSP) 3) Patients with type 2 diabetes who have been undergoing diet therapy and taking DPP-4 inhibitors for 3 month. Among DPP-4 inhibitors, teneligliptin has to be used for at least 1 week before the entry. 4) Written informed consent

Exclusion criteria

Exclusion criteria: 1) hypersensitivity to canagliflozin or teneligliptin/ canagliflozin combination tablet. 2) uncontrolled diabetic retinopathy 3) severe liver dysfunction, renal dysfunction, or heart failure 4) pregnancy, nursing woman or possibly pregnant woman 5) severe diabetic ketosis, diabetic coma 6) severe infection, pre and post operation , severe trauma 7) uncontrolled diet therapy 8) deficiency of insulin secretion 9) BMI < 22kg/m2 10) eGFR < 45ml/min 11) patients who thought to be inappropriate to enter this study for some reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Mean amplitude of glycemic excursions during meal tolerance test	—

Secondary

Measure	Time frame
CGM measurements (M-value, SD, average daily risk range, AUC of blood glucose, MODD, average glucose level during meal tolerance test) Weight Blood pressure	—

Countries

Japan

Contacts

Public ContactKyu Yong Cho

Hokkaido University Hospital Department of Medicine II/Clinical Research and Medical Innovation Center

kyuyong-cho@med.hokudai.ac.jp011-706-5915

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026